Bone Care division has major stakes in the therapeutic segments of Rheumatoid Arthritis and Osteoporosis. It is responsible for bringing the innovative and state of the art therapies to Pakistan in the above mentioned disease areas. Both osteoporosis and rheumatoid arthritis are chronic disease areas and patients need long-term management for improvement of signs with a major emphasis on preservation of quality of life.
Roche pioneered a new era of rheumatoid arthritis management in Pakistan with the launch of the first biologic therapy. Rheumatoid arthritis is a chronic, systemic inflammatory disorder that principally attacks synovial joints but may also affect other tissues and organs and leads to joint deformities and ultimately disability. Exact cause of rheumatoid arthritis is unknown and autoimmunity plays a pivotal role in both its chronicity and progression.
Osteoporosis is the other playing field for the Bone Care division. It is a disease of bones that leads to an increased risk of fracture. Osteoporosis literally means porous bones. It is a silent disease and is most common in women after menopause i.e. postmenopausal osteoporosis, but may also develop in men. Given its influence in the risk of fragility fracture, osteoporosis may significantly affect life expectancy and quality of life.
In addition to currently marketed products, the division has a very strong pipeline encompassing existing as well as some new therapeutic segments like inflammation and auto-immune metabolism, central nervous system and asthma. Like elsewhere, our leadership is entirely based and driven by the trust of health care providers on Roche’s promise of providing innovative and quality solutions for the sufferers around the globe.
Bone Care portfolio:
Please note that Roche is unable to answer questions on individual disease treatment / management matters. These should be discussed with your doctor. As product information and availability varies from country to country, we are able to respond to Pakistan enquiries only. We cannot answer product-related questions through this website.
Bonviva is a nitrogen-containing bisphosphonate available in both dosage forms i.e tablet & Pre-filled syringe. Ibandronate is a highly potent bisphosphonate belonging to the nitrogen-containing group of bisphosphonates, which act on bone tissue and specifically inhibit osteoclast activity. Ibandronate reduces bone resorption, with no direct effect on bone formation. In postmenopausal women, it reduces the elevated rate of bone turnover towards premenopausal levels, leading to a progressive net gain in bone mass.
Bonviva 150 mg tablet:
Bonviva 150mg is indicated for the treatment of postmenopausal osteoporosis, to reduce the risk of fractures. Bonviva 150mg is indicated for the prevention of osteoporosis in postmenopausal women who are not yet osteoporotic, but are at increased risk for fractures.
Bonviva Intravenous Injection:
Bonviva pre-filled syringe is indicated for the treatment of postmenopausal osteoporosis, to reduce the risk of fractures.
- RISTOVA® (RA)
Ristova(Mabthera) in RA
Ristova, the first and only selective B cell therapy for rheumatoid arthritis (RA), represents an innovative treatment option for RA patients and offers lasting treatment success.
Ristova, in combination with methotrexate, is indicated for the treatment of adult patients with severe, active RA who have had an inadequate response or intolerance to current treatment options, including one or more TNF inhibitors.
GPA & MPA
Ristova, the first and only selective B cell therapy for Granulomatosis with polyangiitis (Wegener’s) (GPA) and Microscopic polyangiitis (MPA), represents an innovative treatment option for the therapy of patients with GPA/ MPA. Ristova IV, in combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active Granulomatosis with polyangiitis (Wegener’s) (GPA) and Microscopic polyangiitis (MPA).